NP0077-6D
UKKi029-A
General
Cell Line |
|
| hPSCreg name | UKKi029-A |
| Cite as: | UKKi029-A (RRID:CVCL_RM68) |
| Alternative name(s) |
NP0077-6D
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi034-C (NP0079-C, NP0079-16H) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Familial long QT syndrome UKKi034-A (NP0079-A, NP0079-7B) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Familial long QT syndrome UKKi034-B (NP0079-B, NP0079-15B) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Familial long QT syndrome LUMCi039-A (LQT1-1781G/A hiPSC, LUMC0021iKCNQ-30) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Long QT Syndrome 1 TAUi006-A (UTA.00102.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi006-B (UTA.00118.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi007-A (UTA.00208.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi007-B (UTA.00211.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 |
| Last update | 20th March 2024 |
| User feedback | |
Provider |
|
| Generator | Klinikum der Universität zu Köln (UKK) |
| Distributors | |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA104494405 |
| EBiSC | UKKi029-A |
| Cellosaurus | CVCL_RM68 |
| Wikidata | Q54990505 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 20-24 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | yes |
| Is clinical information available? | yes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA104494406 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | Tomo Saric |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | The clinic in which the donor was recruted holds the medical records |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
| Contact data, institution, or website: | University of Cologne, Institute of Neurophysiology, Tomo Saric |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Independent Ethics Committee of the Faculty of Medicin of the University of Cologne |
| Approval number | DRKS00009433 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Committee of the Faculty of Medicin of the University of Cologne |
| Approval number | DRKS00009433 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Thermo Fisher (CytoTune iPS 2.0 Sendai Reprogramming Kit) |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | Commercial use of this cell line is not permitted |
hIPSC Derivation
General |
|
| Source cell type |
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
|
| Source cell type (free text) | Peripheral Blood Mononuclear Cells; IfGH Münster |
| Age of donor (at collection) | 20-24 |
| Collected in | 2017 |
| Passage number reprogrammed | 0 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining, PCR
|
| Notes on reprogramming vector detection | sendai virus absent |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | morphology |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Vitronectin | |||||||||
| Feeder cells |
No |
|||||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
|||||||||
| O2 Concentration | 20 % | |||||||||
| CO2 Concentration | 5 % | |||||||||
| Medium |
Other medium:
Base medium: StemFlex
Main protein source: Albumine Serum concentration: % Supplements
|
|||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
|||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
|||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
Morphology pictures
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
No larger chromosomal aberrations to be reported.
Passage number: 18
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.